Consequences and costs of noncompliance with iron chelation therapy in patients with transfusion-dependent thalassemia: a literature review.
about
Reducing the iron burden and improving survival in transfusion-dependent thalassemia patients: current perspectivesProfile of deferasirox for the treatment of patients with non-transfusion-dependent thalassemia syndromesEconomic burden of beta-thalassemia/Hb E and beta-thalassemia major in Thai childrenQualitative modification and development of patient- and caregiver-reported outcome measures for iron chelation therapy.Advances in iron chelation therapy: transitioning to a new oral formulation.Iron-chelating therapy for transfusional iron overloadInduction of human fetal hemoglobin via the NRF2 antioxidant response signaling pathwayManagement of transfusional iron overload - differential properties and efficacy of iron chelating agents.Iron chelation adherence to deferoxamine and deferasirox in thalassemia.Disparity in the management of iron overload between patients with sickle cell disease and thalassemia who received transfusions.An update on iron chelation therapyBlood transfusion among thalassemia patients: A single Egyptian center experienceManagement of the thalassemiasd-Propranolol protects against oxidative stress and progressive cardiac dysfunction in iron overloaded ratsEukaryotic initiation factor 2α phosphorylation mediates fetal hemoglobin induction through a post-transcriptional mechanismDeferasirox: appraisal of safety and efficacy in long-term therapy.Cost-utility analysis of deferiprone for the treatment of β-thalassaemia patients with chronic iron overload: a UK perspectiveEmotional impact in beta-thalassaemia major children following cognitive-behavioural family therapy and quality of life of caregiving mothersSynthetic and natural iron chelators: therapeutic potential and clinical useManagement of transfusional iron overload in Latin America: current outlook and expert panel recommendations.Prevention of β Thalassemia in Northern Israel - a Cost-Benefit AnalysisWhich psychosocial factors are related to chelation adherence in thalassemia? A systematic review.An update on disordered iron metabolism and iron overload.Iron chelation therapy for transfusional iron overload: a swift evolution.Deferasirox for the treatment of iron overload in non-transfusion-dependent thalassemia.Current approach to iron chelation in children.A systematic review and meta-analysis of deferiprone monotherapy and in combination with deferoxamine for reduction of iron overload in chronically transfused patients with β-thalassemia.Iron chelation therapy in transfusion-dependent thalassemia patients: current strategies and future directions.Clinical monitoring and management of complications related to chelation therapy in patients with β-thalassemia.Healthcare costs and outcomes of managing β-thalassemia major over 50 years in the United Kingdom.Deferiprone for the treatment of transfusional iron overload in thalassemia.Natural Remedies for the Treatment of Beta-Thalassemia and Sickle Cell Anemia-Current Status and Perspectives in Fetal Hemoglobin Reactivation.Cost-Utility Analysis of Three Iron Chelators Used in Monotherapy for the Treatment of Chronic Iron Overload in β-Thalassaemia Major Patients: An Italian Perspective.Glutathione S-transferase gene polymorphism: Relation to cardiac iron overload in Egyptian patients with Beta Thalassemia Major.Compliance score as a monitoring tool to promote treatment adherence in children with thalassemia major for improved physical growthHealth-Related Quality of Life, Treatment Satisfaction, Adherence and Persistence in β-Thalassemia and Myelodysplastic Syndrome Patients with Iron Overload Receiving Deferasirox: Results from the EPIC Clinical TrialUpdate on the use of deferasirox in the management of iron overload.Socio-psychological impact of infused iron chelation therapy with deferoxamine in metropolitan France: ISOSFER study results.Iron status and treatment modalities in transfusion-dependent patients with myelodysplastic syndromes.Serum ferritin levels and endocrinopathy in medically treated patients with β thalassemia major.
P2860
Q26740347-0CC33B19-8681-4A8D-ACB4-B65FA9DA7AF1Q26771519-BEBD8D55-27D7-4608-BDE9-29344E9A9016Q33533943-D1899442-9CA0-43AD-BC52-583AA6A539CDQ33827300-A294356C-FE3D-445F-A6D4-D9FED11FB1DCQ33879123-AA4EB9AF-08F8-4E85-92A0-05ABB80C091BQ34806460-6968289E-CC19-4A83-9A3A-8CEC69AEFE56Q35037424-97735D89-9DC9-4612-B05D-597251298CBBQ35683841-516779AC-7F96-425F-B9E3-A67996B881DFQ36142495-EA4F5C6E-3F29-4554-A9C0-C23923B574FEQ36185410-5C8E2E3A-74BB-4A07-A93D-3B41AA8126D5Q36393446-ADEBED26-25A9-464E-93BD-816E06B5CD8EQ36732667-F0CB6101-1027-4AED-87D3-09085FB0546DQ36870253-FC10795D-FBA0-4248-8B14-AFBD930B91BDQ37023696-50EA9C53-DED2-4FB5-96F0-C39694A65F2AQ37046975-A7EA0732-465B-4229-9B6F-418B0C54C5E9Q37095523-C485427D-26DB-4B6C-814F-6FE720551A49Q37132320-C377871D-E315-43F6-A0D1-0CB5655C04CCQ37133992-6B3706E5-A25D-4FAD-9E01-29CCD04499A5Q37290073-11424C99-415C-41AC-A1C8-2E6FB7A41F2DQ37372868-66E10EBF-B996-414B-9671-CB06C1C5ECB6Q37663009-2D5CF585-8779-4627-B2A7-328BF3D3314FQ37762810-FA5E8E41-57B7-428D-8E16-C06C19E2F61AQ37791615-79E4E35E-B467-48C3-AB55-5C8418CAAEA4Q37930656-FEC30266-A5EF-4B6B-AAA2-EB5163625140Q38148200-446876A2-6618-4A81-9248-8D2FFC5C3237Q38197269-D7A2E565-E762-443C-A01C-49DF568C0810Q38259421-EF9BCBA5-5162-4F8D-B8AD-6C5DB734F2C1Q38540491-4E222564-CCEC-491C-A303-C5EF2F941C72Q38650293-3AF2737B-217F-4D40-8BAA-B3766D1A8A6BQ38797297-9075249B-8014-464B-BF38-AF7974FE4887Q38817259-2B815C5B-E2ED-4490-AD78-4C8EADF2D37AQ38879274-2C815CED-A64E-4522-9590-785E926910BCQ38968558-855013C1-B534-4B47-9CB4-497DB2CCAC97Q39260470-FFE35187-C19A-4E5C-9EB2-6182A059F2E6Q42040488-1D1AF046-DDDB-48D9-A269-52D42B50AA59Q42098491-7D184E37-8075-47B2-B8C5-E18B06FC7316Q42117340-57FBBCE4-C9A3-479B-BCC3-58FED6C8DAD3Q43235022-4E2BB972-2D37-4C55-B9C4-8C9B290EF367Q43667169-095600B7-EE8C-45C3-BFCD-B40F05CD7BE8Q43934420-BED453C5-9435-460A-99DF-F91D18A7955C
P2860
Consequences and costs of noncompliance with iron chelation therapy in patients with transfusion-dependent thalassemia: a literature review.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Consequences and costs of nonc ...... lassemia: a literature review.
@en
type
label
Consequences and costs of nonc ...... lassemia: a literature review.
@en
prefLabel
Consequences and costs of nonc ...... lassemia: a literature review.
@en
P2093
P2860
P1433
P1476
Consequences and costs of nonc ...... alassemia: a literature review
@en
P2093
Jean-Francois Baladi
John Edelsberg
Oleg Sofrygin
Pradyumna D Phatak
Simu K Thomas
Thomas E Delea
P2860
P304
P356
10.1111/J.1537-2995.2007.01416.X
P577
2007-10-01T00:00:00Z